Evaluation of an in vivo pulmonary aspergillosis model for triazole susceptibility breakpoint development
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01643-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Alex Lepak und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Wisconsin, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Triazoles, Antifungal Agents, Aspergillus fumigatus, Pulmonary Aspergillosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Food and Drug Administration.
Abstract (Originalsprache)
Use of mouse infection models for antimicrobial pharmacokinetic/pharmacodynamic (PK/PD) analysis can assist in dosing regimen design and susceptibility breakpoint development. A major hurdle for clinical translation of in vivo study output is defining the model endpoint linked to clinical success. Validation of the in vivo endpoint requires a clinical data set composed of success or failure linked to minimum inhibitory concentration (MIC), dosing regimen, and if possible human pharmacokinetic measures. The present studies utilized a clinical library of eight Aspergillus fumigatus strains in a mouse pneumonia model to define the endpoint associated with humanized treatment regimens of the triazole, posaconazole. This includes wild-type strains associated with successful treatment and strains with resistance mutations leading to elevated MICs and associated with treatment failure. We found humanized posaconazole exposures resulted in a net stasis or net decrease in organism burden in the animal model compared to the start of therapy for all wild-type strains. However, a net increase in organism burden despite treatment with the humanized regimen was noted for strains with higher MIC values and defined Cyp51 mutations. The ratio of posaconazole free-drug area under the concentration-time curve to the MIC (AUC/MIC) associated with a stasis endpoint in the mouse model was then utilized with in vitro surveillance data and a human posaconazole population pharmacokinetic model to perform simulations and PK/PD target attainment analyses. The results of these analyses demonstrated >90% probability of PK/PD target attainment for A. fumigatus strains with MICs of ≤0.5 mg/L, thus supporting this susceptible breakpoint threshold.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Wisconsin, Madison, Wisconsin, USA.
- Institute for Clinical Pharmacodynamics, Schenectady, New York, USA.
- Element, North Liberty, Iowa, USA.
ORCID-Profile: Sujata M Bhavnani, Christopher M Rubino, M Courtney Safir, Paul Ambrose, David Andes
Förderung
- U.S. Food and Drug Administration
Zitieren
APA
Lepak, A., Bhavnani, S. M., Castanheira, M., Rubino, C. M., Hammel, J. P., Safir, M. C., Massey, J., Hartman, W., Ambrose, P., & Andes, D. (2026). Evaluation of an in vivo pulmonary aspergillosis model for triazole susceptibility breakpoint development. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01643-25
Vancouver
Lepak A, Bhavnani SM, Castanheira M, Rubino CM, Hammel JP, Safir MC, et al. Evaluation of an in vivo pulmonary aspergillosis model for triazole susceptibility breakpoint development. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01643-25
BibTeX
@article{Lepak2026,
author = {Lepak, Alex and Bhavnani, Sujata M and Castanheira, Mariana and Rubino, Christopher M and Hammel, Jeffrey P and Safir, M Courtney and Massey, Justin and Hartman, William and Ambrose, Paul and Andes, David},
title = {Evaluation of an in vivo pulmonary aspergillosis model for triazole susceptibility breakpoint development},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01643-25}
}
EUVIMED